Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measles vaccine at hospital contacts in Guinea-Bissau
NCT04220671Phase 4Enrolling by invitation
- Sponsor
- Bandim Health Project
- Start
- Jan 2020
- Primary completion
- Dec 2026
- Modality
- Live Attenuated Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of measles virus vaccine live in measles and infectious disease (2 arms), sponsored by Bandim Health Project. Primary endpoint: Non-accident mortality or admission at 6 months. Started Jan 2020; status: enrolling by invitation.
02
Drugs
measles virus vaccine live
03
Conditions
measlesinfectious disease
Beyond the preview
Go deeper on NCT04220671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220671.